Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge ; volume:14 ; number:1 ; day:5 ; month:3 ; year:2024 ; pages:1-7 ; date:12.2024
Scientific reports ; 14, Heft 1 (5.3.2024), 1-7, 12.2024

Creator
Chesdachai, Supavit
Rivera, Christina G.
Cole, Kristin C.
Teaford, Hilary R.
Gonzalez Suarez, Maria L.
Larsen, Jennifer J.
Ganesh, Ravindra
Tulledge-Scheitel, Sidna
Razonable, Raymund R.
Contributor
SpringerLink (Online service)

DOI
10.1038/s41598-024-56195-y
URN
urn:nbn:de:101:1-2405101103108.552315893243
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Chesdachai, Supavit
  • Rivera, Christina G.
  • Cole, Kristin C.
  • Teaford, Hilary R.
  • Gonzalez Suarez, Maria L.
  • Larsen, Jennifer J.
  • Ganesh, Ravindra
  • Tulledge-Scheitel, Sidna
  • Razonable, Raymund R.
  • SpringerLink (Online service)

Other Objects (12)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1

Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1

Fatal cases after Omicron BA.1 and BA.2 infection: Results of an autopsy study

Fatal cases after Omicron BA.1 and BA.2 infection: Results of an autopsy study

Fatal cases after Omicron BA.1 and BA.2 infection: results of an autopsy study

Fatal cases after Omicron BA.1 and BA.2 infection: results of an autopsy study

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Sequential viral introductions and spread of BA.1 across Pakistan provinces during the Omicron wave

Sequential viral introductions and spread of BA.1 across Pakistan provinces during the Omicron wave

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Variable detection of Omicron-BA.1 and -BA.2 by SARS-CoV-2 rapid antigen tests

Variable detection of Omicron-BA.1 and -BA.2 by SARS-CoV-2 rapid antigen tests

Related objects